Impact of Chromium Supplementation on Glucido-lipidic Metabolism, Oxidative Stress and Inflammatory State in Patients with Gestational Diabetes

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions
Gestational Diabetes Mellitus (GDM)Oxidative StressInflammatory StatusInsulin ResistanceLeptin ResistanceGlucose Metabolism DisorderLipid Metabolism Disorders
Interventions
DIETARY_SUPPLEMENT

Oral chromium supplementation during gestational diabetes mellitus through the administration of chromium picolinate tablets (200 µg/d)

50 Pregnant women with gestational diabetes mellitus will receive an oral supplementation of 200 µg of chromium picolinate (Nutraxin, B'IOTA Laboratories, Istanbul, Turquie) per day for 06 weeks, starting from their 28th week of pregnancy. 02 fasting blood samples will be taken: one just before the supplementation begins and the other upon its completion, to assess biomarkers of glucose and lipid metabolism, oxidative stress, and inflammation.

DIETARY_SUPPLEMENT

Dietary Supplement: Oral chromium supplementation during gestational diabetes mellitus through the administration of chromium picolinate tablets (400 µg/d)

50 Pregnant women with gestational diabetes mellitus will receive an oral supplementation of 400 µg of chromium picolinate (Nutraxin, B'IOTA Laboratories, Istanbul, Turquie) per day for 06 weeks, starting from their 28th week of pregnancy. 02 fasting blood samples will be taken: one just before the supplementation begins and the other upon its completion, to assess biomarkers of glucose and lipid metabolism, oxidative stress, and inflammation.

Trial Locations (1)

30000

Mohamed Boudiaf Hospital, Ouargla, Ouargla

All Listed Sponsors
lead

University of Kasdi Merbah

OTHER